Stephen M. Ansell

Dr. Ansell is a Consultant, Professor of Medicine, and Clinician-Investigator in the Division of Hematology at the Mayo Clinic. Dr. Ansell’s research activities focus on understanding the biology of B-cell malignancies, including both Hodgkin and non-Hodgkin lymphomas, and Waldenstrom’s macroglobulinemia. His research activities have had a significant impact on patient care, contributing to the development of immune checkpoint therapies in lymphomas.

Dr. Ansell is also co-leader of the Hematological Malignancies Program at the Mayo Clinic Cancer Center, and his extensive research has contributed a multitude of publications within the field. In particular, he is focused on understanding T-cell activation and exhaustion, the function of phagocytic cells in the context of tumors, and the role of cytokines and immunologically active signals in the promotion or suppression of tumor growth and immunoglobulin production. Aside from his clinical and research responsibilities, Dr. Ansell holds positions on various scientific advisory boards and committees, such as the International Waldenstrom Macroglobulinemia Foundation, the Leukemia and Lymphoma Society, and the Lymphoma Research Foundation. He is on the editorial board of both the American Journal of Hematology and Blood Cancer Journal. Dr. Ansell has received awards throughout his career for his research and clinical work, most recently receiving the Ernest Beutler Award from the American Society of Hematology, recognizing his achievements in clinical science and translational research.